

budesonide ER tablet (UCERIS)

Diagnosis Considered for Coverage:

Tablet

- Ulcerative colitis (UC) – induction of remission
- Microscopic colitis
- Auto-immune hepatitis
- Graft vs host disease (GvHD)

Coverage Criteria:

For mild ulcerative colitis:

- Recommended by a gastroenterologist, **and**
- Being used for induction of remission in active ulcerative colitis, **and**
- Inadequate response, intolerable side effect, or contraindication to one preferred mesalamine class agent (e.g. balsalazide, Apriso, Lialda), **and**
- Dose does not exceed 9 mg per day.

Coverage Duration: 8 weeks

For moderate ulcerative colitis:

- Recommended by a gastroenterologist, **and**
- Being used for induction of remission in active ulcerative colitis, **and**
- Inadequate response, intolerable side effect, or contraindication to one preferred mesalamine class agent (e.g. balsalazide, Apriso, Lialda), **and**
- Dose does not exceed 9 mg per day, **and**
- Patient unable to use a preferred oral generic available corticosteroid agent including prednisone, methylprednisolone, hydrocortisone, and dexamethasone.

Coverage Duration: 8 weeks

For microscopic colitis:

Induction of remission

- Recommended by gastroenterologist or infectious disease, **and**
- Dose does not exceed 9 mg per day.

Coverage Duration: 8 weeks

Maintenance of remission

- Recurrence of symptoms (i.e. persistent diarrhea, abdominal bloating/cramping/pain) following completion of induction therapy **and**
- Dose does not exceed 9 mg per day.

Coverage Duration: one year

For auto-immune hepatitis:

- Recommended by a hepatitis specialist (hepatologist, a gastroenterologist, or an infectious disease specialist), **and**
- Being used in combination with azathioprine, **and**
- Intolerance or contraindication to prednisone and prednisolone, **and**
- Dose does not exceed 9 mg per day.

Coverage Duration: one year

For GVHD:

- Patient has GI or liver involvement, **and**
- Dose does not exceed 9 mg per day.

Coverage Duration: one year

Coverage Duration: see above

Effective Date: 5/31/2023